Marta Lavrador

Prof. Marta Lavrador

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 October 2019 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
RCRosário Carvalho
Rosário Carvalho
Marta LavradorMarta Lavrador
Marta Lavrador
ACAna Cristina Cabral
Ana Cristina Cabral
MVManuel T. Veríssimo
Manuel T. Veríssimo
Isabel V. FigueiredoIsabel V. Figueiredo
Isabel V. Figueiredo
Maria Margarida Castel-BrancoMaria Margarida Castel-Branco
Maria Margarida Castel-Branco

29 August 2020 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
Marta LavradorMarta Lavrador
Marta Lavrador
ACAna Cristina Cabral
Ana Cristina Cabral
Isabel V. FigueiredoIsabel V. Figueiredo
Isabel V. Figueiredo
MVManuel T. Veríssimo
Manuel T. Veríssimo
Maria Margarida Castel-BrancoMaria Margarida Castel-Branco
Maria Margarida Castel-Branco
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos

14 March 2022 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
JOJoelizy Oliveira
Joelizy Oliveira
TSThaís Costa E Silva
Thaís Costa E Silva
ACAna Cristina Cabral
Ana Cristina Cabral
Marta LavradorMarta Lavrador
Marta Lavrador
FAFilipe F. Almeida
Filipe F. Almeida
Maria Margarida Castel-BrancoMaria Margarida Castel-Branco
Maria Margarida Castel-Branco
Background: Therapy management in patients suffering from mental health disorders is complex and the risks derived from changes or interruptions of treatment should not be ignored. Medication reconciliation in psychiatry may reduce medication errors and promote patient safety during transitions of care. Objective: To identify the influence of complementary information sources in the construction of the best possible medication history, and to ascertain the potential clinical impact of discrepancies identified in a medication reconciliation service. Methods: An observational study was conducted in an acute mental hospital unit, with a further validation in an internal medicine unit. Adult patients taking at least one medicine admitted in the unit were included. Patients/caregivers were interviewed upon admission and the information gathered was compared with hospital medical and shared electronic medical records. Once the best possible medication history was gathered, therapeutic information was reconciled against the prescription on admission to identify discrepancies. Potential clinical impact of medication errors was classified using the International Safety Classification. Results: During the study period, 148 patients were admitted, 50.7% females, mean age 54.6 years (SD=16.3). Collaboration of a caregiver was a needed in 74% of the interviews. In total, 1,147 drugs were considered to obtain patients’ best possible medication history. After reconciliation, 560 clinically sound intentional discrepancies were identified and 359 discrepancies required further clarification from prescribers: 84.12% “drug omission”, 5.57% “drug substitution”, 6.96% “dose change”, and 3.34% “dosage frequency change”. Potential clinical impact of these medication discrepancies was classified as: 95 mild, 100 moderate, and 29 severe medication errors. Conclusion: About 1 in three intentional discrepancies observed in a pharmacists-led medication reconciliation service required further clarification from prescribers, being 80% of them unintentional discrepancies. Results highlight the importance of the caregiver as source of information for the psychiatric patient, the relevance of analyzing shared electronic health records until 6 months before, and the need to use hospital medical records efficiently. Additionally, 29 discrepancies were classified as errors with potentially severe clinical impact. A medication reconciliation service is concluded to be feasible and necessary in a mental health unit. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

17 June 2023 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
ACAna Cristina Cabral
Ana Cristina Cabral
Marta LavradorMarta Lavrador
Marta Lavrador
Maria Margarida Castel-BrancoMaria Margarida Castel-Branco
Maria Margarida Castel-Branco
Isabel V. FigueiredoIsabel V. Figueiredo
Isabel V. Figueiredo
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos
Background: Different questionnaires assess self-reported medication adherence and others quantify aspects of patients attitudes towards medication, but not together in a single instrument. Gathering these two aspects in a single instrument could reduce patients survey burden. Aim: The aim of this study was to develop the Medication Adherence Universal Questionnaire (MAUQ) using the Maastricht Utrecht Adherence in Hypertension short version (MUAH-16) factorial structure as the hypothesized model. Method: A multistep process started with the modification of the MUAH-16 to obtain the MAUQ. Patients using at least one antihypertensive medicine were recruited. The two questionnaires, the MUAH-16 and MAUQ, were applied. A confirmatory factor analysis (CFA) was performed using the initial MUAH-16 s-order 4-factor model. An additional bifactor model with four uncorrelated factors and an overall score was tested. The comparative fit index (CFI), root mean square error of approximation (RMSEA) with confidence intervals (CIs), and standardized root mean squared residual (SRMR) were used to assess both models. Results: A sample of 300 hypertensive patients completed the instruments. The CFA with the second-order 4-factor solution resulted in similar results for the MUAH-16 and MAUQ: CFIs of 0.934 and 0.930, RMSEAs of 0.043 [CI 0.030–0.056] and 0.045 [CI 0.031–0.057] and SRMRs of 0.060 and 0.061, respectively. The CFA with the bifactor model showed slightly better results for both the MUAH-16 and MAUQ: CFIs of 0.974 and 0.976, RMSEAs of 0.030 [CI 0.005–0.046] and 0.028 [CI 0.001–0.044], and SRMRs of 0.043 and 0.044, respectively. Conclusion: CFA demonstrated that the MAUQ presented a better fit to both models than the MUAH-16, obtaining a robust universal free instrument to assess medicine-taking behaviour and four medicine beliefs components.

18 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMiguel Dias Capinha
Miguel Dias Capinha
Marta LavradorMarta Lavrador
Marta Lavrador
JLJoana Liberato
Joana Liberato
APAdriana Pinheiro
Adriana Pinheiro
AAAna Sofia Dias Aveiro
Ana Sofia Dias Aveiro
Maria Margarida Castel-BrancoMaria Margarida Castel-Branco
Maria Margarida Castel-Branco
Background: Hyponatremia (serum sodium concentration < 135 mmol/L) represents the most common electrolyte disturbance in clinical practice, particularly among high-risk populations such as older adults. Its severity ranges from moderately severe to life-threatening symptoms, contributing to increased mortality. Its etiology is widely heterogeneous and leads to different classifications according to volume status such as hypovolemic, euvolemic and hypervolemic hyponatremia. Drug-induced hyponatremia presents itself as one of the most prevalent but frequently overlooked causes, since many confounding factors like associated comorbidities and polypharmacy complicate the identification of specific medicines as the main offenders. Objectives: This narrative review was performed to provide a comprehensive analysis on drug-induced hyponatremia, focusing not only on the underlying pharmacological mechanisms, but also on management strategies in clinical practice. Methods: A narrative literature review was conducted using PubMed, Science Direct and Google Scholar. Results: This narrative review focused not only on the most common drug classes to induce hyponatremia through different mechanisms, including diuretics, antidepressants, anticonvulsants, and antipsychotics, but also on other pharmacological classes, that, although to a lesser extent, might also be associated with decreasing serum sodium levels (antineoplastic and immunomodulating agents, drugs acting on digestive and locomotor systems, anti-infective drugs, endocrine diseases drugs, among others). It also explores recommendations on the management of drug-induced hyponatremia and it emphasizes the role of healthcare providers in addressing this electrolyte disorder. Conclusions: As drug-induced hyponatremia poses significant challenges in clinical practice, understanding its mechanisms, coupled with effective management strategies, can enhance patient safety.